Actas Dermo-Sifiliograficas皮肤病与性病学学报
Actas Dermo-Sifiliograficas(英文缩写 ACTAS DERMO-SIFILOGR),ISSN 0001-7310,eISSN 1578-2190,中文译名:皮肤病与性病学学报 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 未收录 | N/A |
| 2022 | 3.200 | N/A |
| 2023 | 3.800 | Q1 |
| 2024 | 2.800 | Q2 |
| 2025 | 2.900 | Q2 |
Actas Dermo-Sifiliograficas 最新收录文献
-
1. Erythema papulatum centrifugum: a clinically distinct dermatosis.
1. 离心性丘疹性红斑：一种临床独特的皮肤病PMID:日期:2026-09-19该文献暂无摘要。
-
2. CUDERMA project: Delphi consensus on quality indicators for certification of dermatology units providing care for hidradenitis suppurativa.
2. CUDERMA项目：关于化脓性汗腺炎诊疗皮肤科单位认证质量指标的德尔菲共识PMID:日期:2026-09-19The AEDV CUDERMA project aims to certify dermatology units to standardize clinical practice and ensure quality of care. In line with previous initiatives in psoriasis and dermato-oncology, this study aimed to reach consensus on the aspects to be assessed through quality indicators for the certification of hidradenitis suppurativa (HS) units. A literature review and a focus group involving dermatologists specializing in the management of patients with HS were conducted to develop a preliminary set of quality indicators, which were subsequently reviewed by a multidisciplinary group of experts. The relevance of these preliminary indicators was then evaluated by a Delphi panel comprising 43 members of the Spanish Hidradenitis Suppurativa Working Group. The Delphi panel reached consensus on the inclusion of 52 quality indicators. These indicators will subsequently be standardized for the development of the certification standard for HS units.
-
3. Intralesional bleomycin versus cryotherapy for the treatment of common warts: a systematic review and meta-analysis of randomized controlled trials.
PMID:日期:2026-09-19Cryotherapy is a well-established treatment for common warts. However, the efficacy of bleomycin in the treatment of this condition is less well established. Therefore, we conducted a meta-analysis to compare the efficacy of bleomycin versus cryotherapy for the treatment of common warts. PubMed, Scopus, and Cochrane databases were searched for randomized controlled trials that compared bleomycin with cryotherapy for the management of common warts and reported the outcomes of (1) lack of complete clinical clearance at the patient level (patients with at least 1 residual wart at the end of follow-up) and (2) proportion of warts not completely cleared at the lesion level. Heterogeneity was examined using the I² statistic. A random-effects model was used for outcomes with high heterogeneity. We included 4 randomized controlled trials (RCTs) with 489 patients, of whom 247 (50.2%) received bleomycin. Follow-up intervals ranged from 2 to 3 weeks, with a maximum follow-up of 12 weeks; therefore, only short-term outcomes were available. Lack of complete clinical clearance at the patient level (RR, 1.26; 95%CI, 1.16-1.38; P < .00001; Figure 2A) and the proportion of warts not completely cleared at the lesion level (RR, 1.13; 95%CI, 1.05-1.21; P= .0006; Figure 2B) were significantly more common in patients treated with cryotherapy than in those treated with bleomycin. In patients with common warts, intralesional bleomycin may be associated with higher short-term clearance than cryotherapy. However, these short-term findings are based on a very small number of heterogeneous randomized controlled trials with follow-up of up to 12 weeks, and recurrence and long-term cure could not be assessed. The certainty of the evidence is therefore low, and the results should be interpreted with great caution. In clinical practice, any potential gain in short-term clearance with intralesional bleomycin needs to be weighed against its greater procedure-related pain and local adverse events, as well as factors such as accessibility, clinical expertise, and individual patient preferences.
-
5. Acro-osteolysis and the relevance of mat-like telangiectasia in scleroderma.
PMID:日期:2026-09-18该文献暂无摘要。
-
7. Onychomycosis: clinical and dermoscopic characteristics, diagnosis, and therapeutic management.
7. 甲真菌病：临床与皮肤镜特征、诊断及治疗管理PMID:日期:2026-09-18Onychomycosis is a chronic and recurrent nail infection whose worldwide prevalence continues to increase, affecting 5%-10% of the general population and up to 50% of individuals older than 70 years. Despite the availability of multiple effective therapeutic options, current management practices remain suboptimal, and recurrence rates continue to be high. Recent evidence points to persistent shortcomings in clinical practice, including the underuse of confirmatory diagnostic tests, which entails a greater risk of diagnostic errors, and the frequent initiation of empirical treatment without prior etiological verification, which is associated with treatment failure and resistance, lack of adherence, and persistence of infection. Overall, onychomycosis remains a prevalent and complex clinical problem whose control requires greater diagnostic accuracy, rational use of antifungal agents, and standardized strategies for follow-up and prevention of recurrence.
-
8. Adverse events associated with topical corticosteroid use in moderate-to-severe atopic dermatitis: a prospective analysis from the BIOBADATOP registry.
8. 中重度特应性皮炎局部使用糖皮质激素相关的不良事件：来自BIOBADATOP登记处的前瞻性分析PMID:日期:2026-09-17The long-term safety of topical corticosteroids (TCS) in atopic dermatitis (AD) continues to generate uncertainty and has been identified as a research priority. This study aimed to prospectively evaluate adverse events (AEs) associated with TCS use in the BIOBADATOP registry. A total of 660 patients were included, of whom 484 (73.3%) used TCS at baseline and/or during follow-up. The median baseline EASI score was 21, and baseline disease severity was similar between TCS users and non-users. During TCS treatment, AEs were reported in 4 of 484 patients (0.8%; 95%CI, 0.2-2.1%), all of which were mild: striae, pityriasis sicca of the scalp, hypertension, and mild hypertriglyceridemia. These real-world findings support the safety profile of TCS and make it difficult to justify descriptions of large populations as being intolerant to, or at increased risk from, TCS.
-
9. AEDV 2025-2030 Strategic Plan for Public-Sector Dermatology.
9. AEDV 2025-2030年公共部门皮肤病学战略计划PMID:日期:2026-09-17Public hospital dermatology in Spain faces an increasingly complex environment characterized by health care pressure, the incorporation of therapeutic and technological innovation, structural limitations of the health care system, and regional inequalities in access to care. Against this background, the Spanish Academy of Dermatology and Venereology (AEDV) promoted the development of its 2025-2030 Strategic Plan. The plan was developed using a consultative and participatory approach based on a structured survey of dermatologists with clinical experience in the public health care system and representative roles within the AEDV. Based on the results, a SWOT analysis was conducted to define priority areas for action, strategic objectives, and associated actions. The actions were subsequently prioritized according to their relevance and feasibility using a second online questionnaire. Measures of central tendency and dispersion were calculated for each action, allowing a structured comparative classification according to predefined quantitative criteria. The strategic assessment identified relevant strengths, including a high level of professional specialization and research capacity, together with structural weaknesses, including health care overload and regional inequalities. The prioritization exercise enabled the actions to be classified into four categories, identifying initiatives with potential for immediate impact and others of a structural nature to be developed over the medium to long term. The 2025-2030 Strategic Plan is an implementation-oriented tool that provides a pragmatic roadmap for strengthening public hospital dermatology and the role of the AEDV within the public health care system. The plan also incorporates a preliminary monitoring framework based on outcome-oriented strategic indicators.
-
10. Patch testing with limonene and linalool hydroperoxides: higher yield with higher concentrations in a multicenter observational REIDAC* study of 10,502 patients.
10. 使用柠檬烯和芳樟醇氢过氧化物进行斑贴试验：在一项纳入10,502名患者的多中心观察性REIDAC*研究中，更高浓度可获得更高阳性检出率PMID:日期:2026-09-17Limonene hydroperoxides (Lim-OOHs) 0.2% and 0.3% and linalool hydroperoxides (Lin-OOHs) 0.5% and 1% are terpenes included in the Spanish standard and extended series. The use of both concentrations is currently being evaluated in clinical practice. To evaluate the performance of both concentrations in consecutive patch testing of patients evaluated at dermatology centers in Spain reporting to the Spanish Contact Dermatitis and Cutaneous Allergy Research Registry (REIDAC). A multicenter, cross-sectional, observational study was conducted. Clinical and demographic characteristics were described for patients consecutively patch tested with limonene hydroperoxides (0.3% and 0.2%) and linalool hydroperoxides (1% and 0.5%) between January 2019 and December 2024. Patch test results were analyzed for each concentration, and their usefulness in clinical practice was assessed. Among the 10,502 patients included, the frequency of positive reactions was 2% and 4.1% to Lim-OOHs 0.2% and 0.3%, respectively, and 2.9% and 5.3% to Lin-OOHs 0.5% and 1%, respectively. The higher concentrations detected a greater number of positive, doubtful, and irritant reactions, with low concordance between concentrations. The loss of positive cases when using only the higher concentrations was limited, and the detection efficiency of the lower concentrations was low. Lim-OOHs 0.3% and Lin-OOHs 1% showed better diagnostic performance, with a limited loss of clinically relevant cases, and could therefore be considered more appropriate for the assessment of contact dermatitis caused by these hydroperoxides.